Dear Editor, Several cases of drug-induced pneumonitis in patients treated with imatinib have been reported to date [1] . Here, we report acute drug-induced pneumonitis necessitating therapy discontinuation in a 54-year-old man with primary myelofibrosis (PMF) treated with imatinib. We extended our observation by serial assessment of serum cytokine levels in an attempt to possibly gain further insight in the pathomechanism causing the adverse pulmonary event.
The patient initially underwent a work up because of unexplained thrombo-(639,000/μL) and leucocytosis (WBC 12,200/μL). He had splenomegalia, but was otherwise asymptomatic. The bone marrow aspirate revealed a diagnosis of primary myelofibrosis, grade 3. A specific treatment was initially considered not necessary; however, as the disease became progressive, a therapy with imatinib according to a study protocol investigating the effectiveness of imatinib in PMF was initiated. Imatinib was given in a dosage of 200 mg twice daily, which he had tolerated well over a period of 9 weeks. When imatinib was increased to 600 mg daily, the patient presented with rapidly worsening dyspnoea. Arterial blood gas analysis (ABG) showed hypoxemia and signs of impaired alveolar gas diffusion aggravated under exercise ( Table 1) . The pulmonary function test (PFT) showed a restrictive ventilatory pattern characteristic of interstitial lung disease (Table 2) . Chest high-resolution computed tomography (HRCT) showed poorly defined, bilateral patchy infiltrates (Fig. 1a) consistent with drug-induced pulmonary lesions. Imatinib therapy was stopped and therapy with 1 mg/kg oral prednisolone once daily was started in a tapering fashion and eventually withdrawn after 10 weeks. At the first follow-up visit 9 weeks after the acute episode, the patient's condition had consistently improved. Concomitant with his clinical improvement, ABG and PFT improved (Tables 1 and 2 ). Radiological follow-up by HRCT also revealed a visible improvement although still showing mild patchy infiltrates and leaving traction bronchiectasis as sign of scarification of lung tissue following drug-induced interstitial pneumonia (Fig. 1b) .
Platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and interferon-gamma (IFN-γ) serum concentrations were retrospectively analysed with a specific enzymelinked immunosorbent assay (ELISA, Quantikine, R&D Systems, Minneapolis, MN, USA) according to manufacturer's instructions. Serum cytokine profiles showed further upregulation of already over the range of reference values in healthy individuals elevated profibrotic and angiogenic cytokines (PDGF, VFGF, and bFGF), whereas a major antifibrotic cytokine, IFN-γ, was not detectable (Table 3) . According to the manufacturer R&D Systems, the ELISA range of values in healthy subjects for PDGF is 10.499-29.463 pg/mL, VEGF 62-707 pg/mL, bFGF non-detectable to 14.6 pg/mL, and IFN-gamma less than the lowest IFNgamma standard, 15.6 pg/mL. Instead, in our patient, cytokine levels were elevated, with VEGF and bFGF being far beyond the reported normal range of healthy subjects. Altogether, the maximal cytokine increase of PDGF, VFGF, and bFGF from the patient baseline value measured before starting imatinib therapy was 41%, 55%, and 51%, respectively. Concerning IFN-gamma, as stated above, it is normally not detectable in the serum of healthy individuals but raises most notably during infections. In our patient, IFN-gamma was not detectable at any time during the observation period.
In comparison, in other chronic myeloproliferative disorders, maximal VEGF serum levels were 178 pg/mL, respectively, bFGF 43 pg/mL in essential thrombocytopenia [2] . In the collagen disease polymyositis/dermatomyositis VEGF serum levels were as high as 352 pg/mL [3] . In a study examining serum levels of VEGF and bFGF in metastatic cancer patients, the reported preoperative values were up to 479 and 11.4 pg/mL, respectively [4] .
Ex vivo cell culture experiments using squamous tumour cells of head and neck carcinoma treated with imatinib resulted in reduced cytokine secretion of PDGF and VEGF [5] . Other in vitro experiments showed antigen-specific inhibition of IFN-gamma production by T cells [6] and demonstrated increased IFN-gamma production in imatinibtreated T cells of CML patients [7] . A more recent study revealed that imatinib therapy had no effect on the plasma level of VEGF, PDGF, bFGF, but in vitro inhibitory effect on IFN-gamma production [8] .
In the present report, we describe the case of a patient with PMF in whom treatment with imatinib led to severe, although reversible, interstitial lung disease. Drug-induced pneumonitis usually represents a severe adverse event described for numerous drugs (more information available at www.pneumotox.com). The pathomechanisms are Arterial blood gas parameters at rest and under exercise (under parenthesis) during acute drug-induced pneumonitis and after discontinuation of imatinib at 9-week follow-up
PaO2 arterial oxygen pressure, PaCO2 arterial carbon dioxide pressure, AaDO2 alveolo-arterial oxygen difference, DLCO diffusing capacity for carbon monoxide, DLCO/VA ratio of diffusing capacity for carbon monoxide and alveolar volume Pulmonary function test parameters during acute drug-induced pneumonitis and after discontinuation of imatinib at 9-week follow-up VC vital capacity, FEV1 forced expiratory volume in 1 s, FEV1%VC ratio of forced expiratory volume in 1 s and vital capacity, TLC total lung capacity Serum cytokine concentrations (in pg/mL) before, during (week5-week17) and after therapy with imatinib. Prednisolone was given from week17 until week27 in tapering fashion believed to involve accumulation of inflammatory or immune effector cells and a direct toxic mechanism resulting in lung parenchymal cell injury and subsequent fibrotic response. The underlying molecular mechanisms still remain poorly understood. However, experimental models of interstitial lung disease based on bleomycin [9] and radiation injury [10] have shown a pivotal role for cytokines known to have profibrotic properties in the development of interstitial lung disease and beneficial effects in antagonising them. In our particular case, serum cytokine profiles have been monitored showing consistent upregulation of profibrotic and angiogenic cytokines (PDGF, VFGF, and bFGF) akin to the aforementioned reports (Table 3) . Although limited by a single case, this observation suggests that caution should be given under circumstances of upregulated profibrotic and angiogenic cytokines, as those patients may potentially be at risk for developing adverse events based on upregulation of profibrotic mechanisms. Whereas imitanib has been shown to lead to regression of bone marrow fibrosis possibly by an anti-PDGF effect and through reduction of tissue growth factor-beta (TGF-beta) release from megakaryocytes [11] , profibrotic and angiogenic cytokines tended to be highest during the acute presentation of the adverse event while the patient was taking imatinib, suggesting tissue-specific cytokine responsivity.
In conclusion, our observation suggests to carefully observe pulmonary symptoms in all patients who are receiving imatinib, as early diagnosis and immediate intervention are critical in managing drug-induced interstitial lung disease. In addition, based on this analysis, monitoring the mentioned cytokine profiles could help to timely recognise a "proinflammatory/profibrotic constellation" during imatinib therapy potentially leading to a lifethreatening adverse event. Ultimately, further investigations on a larger scale are needed to elucidate imatinib-related and, in general, the understanding of drug-related interstitial lung disease.
